Physician profile
Felix Bopp
NPI 1518967017
$7,894.28
in general payments reported to CMS, 2019-2025
32 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $734 · 2021: $1,541 · 2022: $938 · 2023: $195 · 2024: $1,008 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,259.76 | 2019-2025 | |
| Allergan, INC. | $779.53 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $620.96 | 2020-2025 | Odomzo, Blu-U, Absorica Ld |
| Galderma Laboratories, L.P. | $572.59 | 2019-2025 | Dysport |
| Revance Therapeutics, INC. | $570.99 | 2024-2025 | Daxxify, Daxi |
| Genzyme Corporation | $364.54 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $303.66 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Leo Pharma INC. | $258.07 | 2019-2025 | Anzupgo, Adbry |
| Almirall LLC | $249.42 | 2019-2022 | |
| Incyte Corporation | $224.65 | 2022-2025 | Opzelura |
| Genentech USA, INC. | $222.12 | 2019-2022 | |
| Janssen Biotech, INC. | $171.50 | 2020-2025 | Tremfya |
| Organogenesis INC. | $133.74 | 2021-2024 | |
| Ucb, INC. | $129.39 | 2019-2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $129.07 | 2021-2024 | Clindacin Etz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $125.00 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Sotyktu |
| Dermira, INC. | $122.42 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $96.07 | 2019-2025 | |
| Pfizer INC. | $88.14 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $71.53 | 2019 | |
| Abbvie INC. | $66.69 | 2024-2025 | |
| Journey Medical Corporation | $45.44 | 2022-2023 | |
| Amgen INC. | $27.27 | 2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $23.01 | 2025 | Libtayo |
| Biofrontera INC. | $18.94 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Lilly USA, LLC | $18.59 | 2025 | Ebglyss |
| Helsinn Therapeutics (U.S.), INC. | $18.04 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.96 | 2023 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $15.14 | 2023 | Seglentis |
| Acelrx Pharmaceuticals, INC. | $14.07 | 2022 | |
| Misonix INC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Bopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.